DIDRONEL
LOE Approachingetidronate disodium
NDAINJECTIONINJECTABLE
Approved
Apr 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIDRONEL (etidronate disodium) is a bisphosphonate delivered by injection used primarily for heterotopic ossification (abnormal bone formation) and Paget's disease of bone. It works by inhibiting osteoclast-mediated bone resorption and reducing abnormal bone turnover. This is an older, well-established small molecule therapy with limited modern clinical development.
LOE Approaching
Limited growth trajectory with approaching loss of exclusivity suggests a consolidating franchise with reduced commercial team investment and focus on legacy market maintenance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIDRONEL offers minimal career growth due to its LOE-approaching status and zero linked job openings. This role is best suited for professionals managing legacy products or seeking specialty pharma/niche market exposure rather than high-growth brand building.
Brand ManagerMarket Access Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.